Skip to main content
Kukje Pharma Co., Ltd. logo

Kukje Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 002720 ISIN · KR7002720001 KO Manufacturing
Open in API
Filings indexed 296 across all filing types
Latest filing 2026-05-20 Capital/Financing Update
Country KR South Korea
Listing KO 002720

About Kukje Pharma Co., Ltd.

https://www.kukjepharm.co.kr/index.php?…

Kukje Pharma Co., Ltd. is a company engaged in the manufacturing, distribution, import, and export of pharmaceutical products, cosmetics, and health supplements. Its core offerings include a wide range of prescription (ETC) and over-the-counter (OTC) drugs, with a notable specialization in antibiotics such as Cephalosporins. In addition to its primary pharmaceutical business, the company also develops and markets cosmetic products, food supplements, and respiratory protection face masks. The company serves both domestic and international markets.

Recent filings

Filing Released Lang Actions
[기재정정]타인에대한채무보증결정
Capital/Financing Update Classification · 85% confidence The document is a formal corporate announcement of a debt guarantee decision (and its correction) for an affiliate, detailing guarantee amounts, periods, board resolution dates and related financial ratios. It does not contain general financial statements or investor presentation material, nor is it about share issuance or buybacks. It is a financing‐related regulatory update on contingent liabilities (debt guarantee), which best fits the Capital/Financing Update category (CAP).
2026-05-20 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 93% confidence The document is titled “분기보고서” (Quarterly Report) for the 69th fiscal period covering 2026-01-01 to 2026-03-31. It contains comprehensive financial statements, business overview, Q1 revenue, profit figures, asset tables, and detailed analysis. It is the actual interim financial report itself, not merely an announcement or certification. Therefore it is classified as an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 95% confidence The document is a filing to the Korean Financial Supervisory Service/Korea Exchange reporting the appointment, dismissal, or mid-term retirement of outside directors. This is a direct announcement of changes in the company’s board of directors (outside directors). Therefore, it falls under Board/Management Information.
2026-03-26 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 91% confidence The document is the official results of the company’s 2026 Annual General Meeting, listing each agenda item, vote outcomes (approval status, percentages, counts), and details of resolutions (financial statements approval, dividend, director appointments). This matches the “Declaration of Voting Results & Voting Rights Announcements” category rather than materials (AGM-R) or other filings.
2026-03-26 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for Kukje Pharma Co., Ltd. (국제약품주식회사) covering the fiscal years 2024 and 2025. It includes the independent auditor's report, consolidated financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. While it contains financial data, it is the formal audit report issued by an external accounting firm (Daesung Accounting Corp), which is distinct from a 10-K (which is a broader regulatory filing) or an Earnings Release. Therefore, it is classified as an Audit Report. FY 2025
2026-03-18 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from Kukje Pharma. It provides the audit opinion, financial highlights (assets, liabilities, equity, profit/loss), and auditor information. While it contains financial data, it is a standard regulatory disclosure announcement in the Korean market (DART/KIND system) confirming the receipt and submission of the audit report, rather than the full annual report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2025
2026-03-17 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.